Welcome to our dedicated page for Curevac B.V. news (Ticker: CVAC), a resource for investors and traders seeking the latest updates and insights on Curevac B.V. stock.
CureVac B.V. (CVAC) is a clinical-stage biopharmaceutical leader pioneering mRNA technology for vaccines and cancer therapies. This page provides investors and industry professionals with timely updates on corporate developments, regulatory milestones, and scientific advancements.
Access verified press releases, earnings reports, and partnership announcements in one centralized location. Track progress across CureVac's clinical pipeline, including prophylactic vaccines, oncology treatments, and molecular therapies leveraging their proprietary mRNA platform.
Key updates cover:
• Clinical trial results
• Strategic collaborations with global partners
• Regulatory filings and manufacturing developments
• Financial performance and corporate communications
Bookmark this page for direct access to CureVac's official announcements, ensuring you stay informed about innovations in mRNA-based medicine and their market implications.
CureVac N.V. (Nasdaq:CVAC) reported its financial results for the fourth quarter and full year 2022, showcasing a significant transformation in its operations driven by clinical advancements in COVID-19 and flu together with a broadened oncology footprint. The company achieved positive preliminary Phase 1 data for its modified COVID-19 candidate CV0501 and flu candidate Flu-SV-mRNA, demonstrating good tolerability and strong immune responses across age groups. CureVac ended 2022 with €495.8 million in cash, down from €811.5 million the previous year, driven by R&D expenditures. Revenue fell to €67.4 million from €103.0 million, primarily due to the cessation of collaborations and focused program adjustments. The operating loss for the year was €249.5 million, reflecting increased strategic investments.
FAQ
What is the current stock price of Curevac B.V. (CVAC)?
What is the market cap of Curevac B.V. (CVAC)?
